Axtria Thought Leadership
Executive insights and perspectives on the Life Sciences industry
White Paper
One Important Lesson From Biogen’s Surprise Announcement On Hopes For An Alzheimer’s Drug
This white paper lays out the reasons for these changes and action steps executives must make to shift from the current volume-based to value/outcomes-based commercial model design ...
White Paper
Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary
This commentary white paper provides reasons why importation is still a bad idea today, but more importantly, why the reintroduction of this policy is a reflection of the broader e ...
White Paper
AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy
This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...
White Paper
How Will The Next Great Recession Affect The US Pharma Industry?
The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroecono ...
White Paper
Perspectives On The Design And Effectiveness Of Pharma Sales Contests
This white paper covers an array of topics pertaining to the development, execution, and outcomes from sales contests to provide sales operations leaders practical guidance on key ...
White Paper
Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?
Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial grow ...
Report
Future Of Pharma: Evolving Commercial Models – Part 2
Learn what several senior pharma commercial operations leaders think of the potential implications of industry challenges on business operations, sales and marketing objectives and ...
White Paper
Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program
This paper explores the reason behind this about-face, potential policy alternatives President Trump may pursue to reduce drug prices and their adverse consequences, and what shoul ...
White Paper
Has Traditional Call Planning Passed Its Prime?
This paper explores simple and more complex additions and solutions to a myriad of issues facing future changes to call planning. A central theme in all the proposed solutions is t ...
